Universitätsklinikum Mainz

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• High blood pressure2 trials
• Melanoma2 trials
• Acute lymphoblastic leukaemia1 trial
• Chronic kidney disease1 trial
• Familial hypercholesterolaemia1 trial
• Glaucoma1 trial

Phase

• Phase 32 trials
• Phase 21 trial

Status

• Active, not recruiting2 trials
• Completed2 trials
• Recruiting1 trial
• Terminated1 trial

Lead sponsor

• Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company1 trial
• Goethe University1 trial
• Hoffmann-La Roche1 trial
• iSTAR Medical1 trial
• Novo Nordisk A/S1 trial
• and 1 more

Running trials

• Active, not recruiting

  Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia

  NCT04579367· Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company· Source

• Active, not recruiting

  MINIject Global Long-Term Follow-up Study

  NCT04524416· iSTAR Medical· Source

• Recruiting

  GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of Adult Acute Lymphoblastic Leukemia (ALL) Patients and Related Diseases Associated With a Prospective Collection of Biomaterial

  NCT02872987· Goethe University· Source

  Contact: Nicola Gökbuget, Dr. med.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute lymphoblastic leukaemia1 recruiting

Closed trials

• Terminated

  Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)

  NCT04968184· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

  NCT02908672· Phase 3· Hoffmann-La Roche· Source

• Completed

  Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

  NCT02902029· Phase 2· University Hospital, Essen· Source